Baisong Mei is the chief medical officer of City Therapeutics. He brings 25 years of industry experience and a strong track record of bringing innovative medicines through clinical development to regulatory approval, including ALPROLIX®, ELOCTATE®, QFITLIATM, JIVI® and ALTUVIIIO®. Dr. Mei is co-inventor of the latter two globally approved drugs, and has led clinical development for multiple new molecular entities including siRNAs, gene therapies, proteins and small molecules.

Previously, Dr. Mei was the executive vice president and chief medical officer at Editas Medicine. In this role, he built a high-performance organization including the clinical development, drug safety, clinical operations, biometrics, regulatory, medical affairs and patient advocacy functions. Prior to Editas, Dr. Mei served a five-year tenure with Sanofi as senior global project head in rare disease and rare blood disorders. Before Sanofi, he served as therapeutic area head for Hematology Clinical Development at Biogen and, earlier in his career, worked in drug discovery research and chemistry, manufacturing and control development at Biogen and Bayer.

Dr. Mei earned a PhD from The University of Toledo in Ohio and completed medical education at Bengbu Medical College and Wuhan University School of Medicine in China. He held postdoctoral fellowships at the University of California San Francisco and the University of California Berkeley.